

Adult CIRB - Early Phase Emphasis Meeting Agenda

October 6, 2026

I Amendment

NRG-GY031, A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN00-3694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer (Version Date 08/21/26)

II Continuing Review

10504, A Phase 2 Study of Atezolizumab with Selinexor in Alveolar Soft Part Sarcoma (AXIOM) (Version Date 06/17/26)

III Continuing Review

10527, A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination with the ATR Inhibitor Tuvusertib (M1774) (Version Date 05/07/26)

IV Continuing Review

10597, A Phase 1 Study of APG-1252 (pelcitoclax) and cobimetinib in recurrent ovarian and endometrial cancers (Version Date 08/24/26)

V Continuing Review

10675, A Randomized Phase 2 Trial of ASTX727 +/- Iadademstat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs) (Version Date 05/28/26)
